ArticleInternational journal of clinical and experimental pathology2021
Expression and clinical significance of PDK family in breast cancer based on data mining.
Article in International journal of clinical and experimental pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Dual activation of cuproptosis and excessive autophagy by copper-bismuth metal-organic frameworks-loaded detachable microneedles in oral leukoplakia.Materials today. Bio · 2026Article
- Herbal Composition Inhibits Mitochondrial Oxidative Phosphorylation to Prevent HER2-Positive Breast Cancer and Identifies Potential Active Compounds.International journal of molecular sciences · 2025Article
- Glucocorticoid receptors orchestrate a convergence of host and cellular stress signals in triple negative breast cancer.The Journal of steroid biochemistry and molecular biology · 2024Review
- Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pyruvate dehydrogenase kinase (PDK) family, including PDK1, PDK2, PDK3, and PDK4, is involved in tumor progression. However, its role in breast cancer (BC) remains unknown. This study aims to mine the expression, clinical significance, and downstream pathways of PDK family in BC. By analyzing data downloaded from The Cancer Genome Atlas (TCGA) database, we found an enhanced level of PDK3 and decreased expression of PDK2 and PDK4 in BC tissues compared to normal tissues. Also, the expression of PDK3 mRNA is negatively related to that of PDK2 and PDK4, while there is a positive relation between PDK2 mRNA expression and PDK3 mRNA expression. Moreover, we found that PDK2 expression is related to lymph node metastasis, and PDK4 is associated with T stage and stage using analysis of data obtained from TCGA database. Finally, we identified several gene sets related to cancer initiation and progression regulated by PDK2-4 after performing Gene set enrichment analysis (GSEA). In conclusion, PDK2-4 possess potential as targets for BC treatment.
Indexed as
Identifiers
33532027PMC7847494W3127479867What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.